Wednesday, January 2, 2019
Fate Therapeutics named a 2019 top pick at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said Fate Therapeutics remains a top pick into 2019 and he reiterated his Overweight rating and $23 price target on the stock, stating that he is “most excited” about Fate’s “disruptive” pipeline of 10 iNK and iT cell induced Pluripotent Stem Cell candidates. The FDA accepted the IND for Fate’s first iNK candidate and he expects initial FT500 data this year to validate Fate’s broader iPSC platform, Tenthoff added.
https://thefly.com/landingPageNews.php?id=2842773
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.